z-logo
Premium
Gangliosides of monocyte‐derived macrophages of adults with advanced HIV infection show reduced surface accessibility
Author(s) -
Berenson Charles S.,
Gallery Melissa A.,
Katari Manpreet S.,
Foster Edward W.,
Pattoli Mark A.
Publication year - 1998
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.64.3.311
Subject(s) - macrophage , monoclonal antibody , biology , monocyte , peripheral blood mononuclear cell , antibody , in vitro , immunology , epitope , immune system , cd68 , immunohistochemistry , biochemistry
Gangliosides of macrophages are potent immunoregulatory molecules. A monoclonal antibody directed at human macrophage gangliosides (25F4) inhibits macrophage migration with relative specificity. Recent reports suggested that greater expression of G m1 in mononuclear cells accompanies advanced HIV infection, although others failed to demonstrate any differences in vitro. We purified gangliosides from blood monocyte‐derived macrophages obtained from HIV‐infected adults. Densitometric analysis of chromatograms demonstrated no differences in relative quantities of any macrophage gangliosides among all HIV‐positive and ‐negative donors. Antibody 25F4 showed equivalent ELISA reactivity with purified macrophage gangliosides of HIV‐positive and ‐negative donors. However, intact macrophages of HIV donors with CD 4 + cell counts <200/mm 3 showed impaired immunofluorescent surface expression of the 25F4 epitope and concomitant loss of migration inhibitory responsiveness. Thus, although relative content is unchanged, macrophage gangliosides become surface‐inaccessible in adults with advanced HIV infection. Our data provide further evidence that dysregulation of glycosphingolipid metabolism in HIV‐1 infection contributes to immune dysfunction. J. Leukoc. Biol . 64: 311–321; 1998.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here